BackIGM Biosciences Overview

IGM Biosciences Current Cash

Latest current cash for IGMS: $31M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$30.65M
↓ 54.43% YoYΔ $-36.61M vs prior year quarter

Peer average

Loading

IGM Biosciences Current Cash History

Loading

IGM Biosciences vs. peers: Current Cash Comparison

Loading

IGM Biosciences Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

IGM Biosciences (IGMS) FAQ

IGM Biosciences (IGMS) currently reports a current cash of $31M as of June 2025. That compares with $67M in the prior-year period — down 54.4% year over year. Use the charts on this page to explore IGM Biosciences's current cash history and peer comparisons.

IGM Biosciences's current cash decreased from $67M to $31M — a 54.4% year-over-year decrease (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

IGM Biosciences reported $31M in current cash as of June 2025. That compares with $67M in the prior-year period — down 54.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $31M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for IGM Biosciences, and consider following IGMS for alerts when major investors trade the stock.

IGM Biosciences is classified in the Healthcare sector. On current cash, it currently shows $31M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IGMS with unrelated industries.